Bringing Value to Pharma and Biopharma

Commercial Healthcare Partners

Apr 29, 2022PAO-04-22-R250-75

Financing The Road to 50 States PA TV (video)

At this stop on the Road to 50 States, Jim Usry, Principal and Founding Partner at Commercial Healthcare Partners, talks to Nigel about how Commercial HealthCare Partners are interacting and bringing value to pharma and biotech companies.

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

PAO-05-26-PA-14May 13, 2026

Tariffs

The Intersection of Pharmaceutical Tariffs, Outsourcing, and Investment: Balance is Key

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-04-26-PA-15Apr 15, 2026

Partnerships

What does a “true strategic partnership” between sponsors and CDMOs look like in today’s environment?

Pharma's Almanac

PAO-03-26-RT-01Mar 1, 2026

CMC and Investment

Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

PAO-01-26-NI-15Jan 15, 2026

R&D Funding

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

PAO-01-26-NI-07Jan 9, 2026

Risk Sharing

Risk-Sharing Rewritten: How Biopharma Partnerships Are Redesigning Incentives Beyond the Deal

David Alvaro, Ph.D.

Pharma's Almanac

PAO-01-26-NI-05Jan 9, 2026

Partnerships

Structured Deals on the Rise: Milestones, Options, and Risk-Sharing in Biopharma Licensing

David Alvaro, Ph.D.

Pharma's Almanac

PAO-01-26-NI-04Jan 8, 2026

Conference

Amgen To Present At The 44Th Annual J.P. Morgan Healthcare Conference

Amgen

PR-01-26-03Jan 7, 2026

Big Science

The Economics of Big Science — and Why It Matters for Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

PAO-01-26-NI-06Jan 6, 2026

Biotech Funding

Selective Capital, Stronger Science: The Emerging Biotech Funding Model

David Alvaro, Ph.D.

Pharma's Almanac

PAO-12-25-NI-04Jan 6, 2026

M&A

How are capital constraints impacting M&A and strategic partnerships in the CDMO and pharma sectors?

Pharma's Almanac

PAO-01-26-RT-02Jan 5, 2026

M&A

Fewer, Bigger, Smarter: How Pharma M&A Evolved in 2025 — and What Comes Next

David Alvaro, Ph.D.

Pharma's Almanac

PAO-12-25-NI-07Dec 17, 2025

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us Nice Insight That's Nice

Reach Our Team

My Account

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Bringing Value to Pharma and Biopharma

Related Content

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

Tariffs

The Intersection of Pharmaceutical Tariffs, Outsourcing, and Investment: Balance is Key

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Partnerships

What does a “true strategic partnership” between sponsors and CDMOs look like in today’s environment?

Pharma's Almanac

CMC and Investment

Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

R&D Funding

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

Risk Sharing

Risk-Sharing Rewritten: How Biopharma Partnerships Are Redesigning Incentives Beyond the Deal

David Alvaro, Ph.D.

Pharma's Almanac

Partnerships

Structured Deals on the Rise: Milestones, Options, and Risk-Sharing in Biopharma Licensing

David Alvaro, Ph.D.

Pharma's Almanac

Conference

Amgen To Present At The 44Th Annual J.P. Morgan Healthcare Conference

Amgen

Big Science

The Economics of Big Science — and Why It Matters for Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Biotech Funding

Selective Capital, Stronger Science: The Emerging Biotech Funding Model

David Alvaro, Ph.D.

Pharma's Almanac

M&A

How are capital constraints impacting M&A and strategic partnerships in the CDMO and pharma sectors?

Pharma's Almanac

M&A

Fewer, Bigger, Smarter: How Pharma M&A Evolved in 2025 — and What Comes Next

David Alvaro, Ph.D.

Pharma's Almanac

Related Content

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

Tariffs

The Intersection of Pharmaceutical Tariffs, Outsourcing, and Investment: Balance is Key

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Partnerships

What does a “true strategic partnership” between sponsors and CDMOs look like in today’s environment?

Pharma's Almanac

CMC and Investment

Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

R&D Funding

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

Risk Sharing

Risk-Sharing Rewritten: How Biopharma Partnerships Are Redesigning Incentives Beyond the Deal

David Alvaro, Ph.D.

Pharma's Almanac

Partnerships

Structured Deals on the Rise: Milestones, Options, and Risk-Sharing in Biopharma Licensing

David Alvaro, Ph.D.

Pharma's Almanac

Conference

Amgen To Present At The 44Th Annual J.P. Morgan Healthcare Conference

Amgen